MedTrace Logo

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

NCT01159665 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-12-17

Study results available
· View outcomes & findings →

Summary

To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)

Conditions

  • Vitrectomy

Interventions

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-11-30
Completion
2011-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159665 on ClinicalTrials.gov